Zhang, Christopher
Wu, Benson Z.
Di Ciano-Oliveira, Caterina
Wu, Yin Fang
Khavkine Binstock, Sharon S.
Soria-Bretones, Isabel
Pham, Nhu-An
Elia, Andrew J.
Chari, Raj
Lam, Wan L. http://orcid.org/0000-0002-0945-0644
Bray, Mark R.
Mak, Tak W.
Tsao, Ming-Sound http://orcid.org/0000-0002-9160-5405
Cescon, David W. http://orcid.org/0000-0002-1080-0998
Thu, Kelsie L. http://orcid.org/0000-0001-9262-7238
Article History
Received: 20 January 2024
Revised: 31 July 2024
Accepted: 14 August 2024
First Online: 24 August 2024
Competing interests
: Christopher Zhang, Benson Z. Wu, Caterina Di Ciano-Oliveira, Yin Fang Wu, Sharon S. Khavkine Binstock, Nhu-An Pham, Andrew J. Elia, Raj Chari, Wan L. Lam, Ming S. Tsao, Kelsie L. Thu – none. Isabel Soria-Bretones - ISB is currently an employee of Repare Therapeutics. Mark Bray - MRB is currently an employee of Treadwell Therapeutics. Tak Mak - Owns equity in Treadwell Therapeutics Inc. and Agios Pharmaceuticals and is a consultant for AstraZeneca and Tessa Therapeutics. David Cescon - DWC reports consultancy and advisory relationships with AstraZeneca, Daiichi Sankyo, Exact Sciences, Eisai, Gilead, GlaxoSmithKline, Inflex, Inivata/NeoGenomics, Lilly, Merck, Novartis, Pfizer, Roche and Saga; research funding to their institution from AstraZeneca, Guardant Health, Gilead, GlaxoSmithKline, Grail, Inivata/NeoGenomics, Knight, Merck, Pfizer, ProteinQure and Roche.
: Tumor tissues were banked after informed written patient consent following a protocol approved by the University Health Network Research Ethics Board.